WO1993015068A1 - Novel benzopyran derivative - Google Patents
Novel benzopyran derivative Download PDFInfo
- Publication number
- WO1993015068A1 WO1993015068A1 PCT/JP1993/000086 JP9300086W WO9315068A1 WO 1993015068 A1 WO1993015068 A1 WO 1993015068A1 JP 9300086 W JP9300086 W JP 9300086W WO 9315068 A1 WO9315068 A1 WO 9315068A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- benzopyran
- lower alkyl
- bisfluoromethyl
- substituent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Definitions
- the present invention relates to a novel benzopyran derivative which is a compound useful as a medicine. [Background technology]
- benzopyran derivatives having various pharmacological actions have been known.
- JP-A Nos. 60-97974, 61-47416, 63-165317, 63-196581, 63-201182, 63-303977, 63-303977, 64-26578, 64-38087, JP-A-2-129184 and Journal of Medicinal Chemistry vol. 33, No. 6, pp. 1529-1541, 1990, etc. state that the carbon atom at position 4 of the benzopyran ring is a nitrogen atom.
- Various benzopyran derivatives that are directly bonded are disclosed, and it is described that these compounds have an antihypertensive effect and can be used for treatment of heart disease and the like.
- Benzopyran derivatives in which the carbon atom at the 4-position of the benzopyran ring is not directly bonded to a nitrogen atom are also described in JP-A-63-303977, JP-A-64-38087, WO 90/14346, Journal of Heterocyclic Chemistry. vo 1.11 (5), pp. 797-802, 1974 and Journal of Medicinal Chemistry vol.33, No.6, p.1529-1541, 1990 and the like.
- W090Z14346 discloses that the benzopyran ring A compound similar to the compound of the present invention having an amide group or a thioamide group at the 4-position has been disclosed.
- the present inventors have studied the synthesis of K and benzopyran derivatives having a K + channel activity equal to or higher than those of these analogous compounds and chromatographic rims, and in which the carbon atom at the 4-position of the benzovirane ring is not directly bonded to the nitrogen atom.
- the present inventors discovered that the following novel benzopyran derivatives not described in the literature have such pharmacological activities, and completed the present invention based on this finding.
- the compound of the present invention is a novel compound represented by the following general formula (I) and has excellent ⁇ + channel action activity.
- Ri represents a hydrogen atom or a hydroxyl group
- R 2 and R 3 are the same or different and are a lower alkyl group, a substituted lower alkyl group having a halogen atom or a lower alkoxy group as a substituent, or Represents a heterocyclic ring having an oxygen atom or an iodine atom as a hetero atom, provided that R 2 and R 3 do not simultaneously represent a lower alkyl group
- R 4 and R 5 are the same or different and represent a hydrogen atom
- X represents a lower alkyl group, a lower haloalkyl group, a halogen atom, a lower alkoxy group, a lower haloalkoxy group, an amino group, an acylamino group, a nitro group, a cyano group, an ester group, a lower alkylsulfonyl group or an arylsulfonyl group.
- Z is a hydrogen atom, lower alkyl group, aryl group, hydroxyl group, lower alkoxy group, cyano group
- canole Y represents one NR 6 R 7 , one OR 8 or one SR 9 , wherein R 6 and R 7 are the same or different and represent a hydrogen atom, a hydroxyl group, a lower alkoxy group, a cyano group, May have a substituent
- the lower alkyl group means an alkyl group having 1 to 6 carbon atoms, and preferably an alkyl group having 1 to 4 carbon atoms.
- Examples of such lower alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl and the like.
- the lower alkoxy group is an alkoxy group having 1 to 6 carbon atoms, such as a methoxy group, an ethoxyquin group, an n-propoxy group, an i-propoxy group, an n-butoxy group, an i-butoxy group, an s-butoxy group, and t.
- a methoxy group such as a methoxy group, an ethoxyquin group, an n-propoxy group, an i-propoxy group, an n-butoxy group, an i-butoxy group, an s-butoxy group, and t.
- a methoxy group such as a methoxy group, an ethoxyquin group, an n-propoxy group, an i-propoxy group, an n-butoxy group, an i-butoxy group, an s-butoxy group, and t.
- One butoxy group and the like can be mentioned.
- the halogen atom means chlorine, fluorine, bromine, and iodine, and is preferably chlorine or fluorine.
- Examples of the substituted lower alkyl group having a halogen atom or a lower alkoxy group as a substituent include a methoxymethyl group and a fluoromethyl group.
- Examples of the heterocyclic ring having an oxygen atom or a hetero atom as a hetero atom include a tetrahydrovinylyl group and a tetrahydrothiopyranyl group.
- acylamino group examples include lower alkylcarboxylic acid amino groups such as acetylamino, amino propionate, amino butyrate, and amino valerate.
- ester group examples include lower alkyl ester groups such as a methyl ester group, an ethyl ester group, a propyl ester group, and a butyl ester group.
- lower alkyl sulfonyl group examples include a methyl sulfonyl group, an ethyl sulfonyl group, a propyl sulfonyl group, Lower alkyl such as butylsulfonyl group And a sulfonyl group.
- arylsulfonyl group examples include a phenylsulfonyl group, a naphthylsulfonyl group, a tolylsulfonyl group, a xylylsulfonyl group, and a biphenylsulfonyl group.
- Examples of the cycloalkyl group which may have a substituent include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group substituted with a halogen atom, a lower alkyl group, or the like.
- a hetero atom such as a pyridyl group, a pyrimidinyl group, a quinolinyl group, a virazinyl group, a thiazolyl group, an oxazolyl group, an imidazolyl group, a thiadiazole group, and a tetrazolyl group.
- Aryl group such as a pyridyl group, a pyrimidinyl group, a quinolinyl group, a virazinyl group, a thiazolyl
- R 2 , 3 > R 4 and R 5 have the same meanings as described above).
- L represents a halogen atom, a leaving group such as one OR 10 or one SO n Ru.
- R 10 and R represent a hydrogen atom, a lower alkyl group.
- n is an integer of 0 to 2) in the presence of a base in an inert solvent.
- the base used herein include sodium hydride, sodium alkoxide, sodium alkoxide, alkyl lithium, carbonated sodium, sodium carbonate, hydroxylated sodium, sodium hydroxide and the like.
- the compound of the present invention represented by the general formula (I) can be obtained by adding a compound represented by the general formula (V) to the compound represented by the general formula ( ⁇ ).
- the compound represented by the general formula (I) also has the general formula (VI)
- the reduction reaction is an inert solvent, the reducing agent for example, NaBH 4, KBH 4, L i BH 4, NaBH 3 CN, or to apply a borohydride or a metal hydride such as L i A 1 H 4, or palladium Performed by catalytic reduction using carbon-Raney nickel, etc. I can.
- the reducing agent for example, NaBH 4, KBH 4, L i BH 4, NaBH 3 CN, or to apply a borohydride or a metal hydride such as L i A 1 H 4, or palladium Performed by catalytic reduction using carbon-Raney nickel, etc. I can.
- the dehydration reaction is carried out in an inert solvent using an acid such as paratoluenesulfonic acid or hydrogen chloride, or in the presence of a base in the presence of a base such as p-toluenesulfonyl chloride or acetyl chloride. This is performed by using an acid anhydride.
- the base used herein include organic bases such as pyridine and triethylamine, and sodium hydroxide, sodium alkoxide, potassium alkoxide, alkyl lithium, carbonated lime, sodium carbonate, hydroxylated lime, sodium hydroxide and the like.
- the compound represented by the general formula (I) is represented by the general formula (Cor)
- R 2 , R 3 , R 4 and R 5 have the same meanings as described above, and an inert solvent, HNR 6 R 7 (where R 6 and R 7 are as defined above) which have the same meaning) are reacted with an appropriate condensing agent.
- condensing agent used here examples include carbonyldiimidazole, amide reagents such as triphenylphosphine and 2,2′-dipyridyldisulfide, and the like.
- the compounds of the present invention represented by the general formula (I) can also be obtained by applying the specific production methods described in the examples.
- the compound of the present invention represented by the general formula (I) shows an excellent K + channel activating effect, as is apparent from the test examples described later, and is a smooth muscle relaxant, that is, an anti-asthmatic agent, an antihypertensive agent, and an antianginal agent. It can be used as an active ingredient of K + channel activators such as sickness agents and therapeutic agents for urinary incontinence.
- the dose of the compound represented by the general formula (I) depends on the type and severity of the disease, but is generally about 0.001 l to lmgZkg /, preferably lmg Z kg Z days.
- the administration route is oral administration, non-administration Oral administration and topical administration can be selected as needed.
- the carrier for the K + channel activator those usually used as carriers can be used.
- Y ′ represents one NR! OR, wherein R 10 and R are the same or different and are a hydrogen atom, a lower alkyl group or a hydroxyl group.
- a compound having a nitro group at the 6-position of the benzopyran ring, such as a compound represented by the formula: Ri, R 2 and R 3 have the same meanings as described above.
- one can represent hydrogen atom of R 8 or R 7 (R 1 () or R) can include the following specific examples of the active strong c present compounds.
- N-Methyl-6-Nitrospiro [2H-1 Benzopyran-1,2,4'-tetrahydropyran] 4-Carbothioamide 200 mg, Iodide 2-Chloro-1-methylpyridinium 192 mg, Triethylamine A mixture of 209 1 and 5 ml of dry tetrahydrofuran was heated under reflux for 2 hours, cooled to room temperature, added with 42 mg of cyanamide and 30 mg of sodium hydride (60%), heated under reflux for 2 hours, added with ice water and extracted with methylene chloride. .
- 6-Bromo-2,2-bisfluoromethyl-N-methyl-2H-1 Benzoviran-4-Ruboamide Using 6-bromo-2,2-bisfluoromethyl-2H-1-benzopyran-4-1-carboxylic acid in the same manner as in Example 7 (3), melting point of 187-188 ° C, 6-bromo-2,2-bis Fluoromethyl-1-N-methyl-2H-1-benzopyran-14-carbamide was obtained.
- 2,2-Bisfluoromethyl-6-trifluoromethyl-2H-1-benzopyran-1-4-carboxylic acid was prepared in the same manner as in Example 10 to give N- (2-cyanoethyl) -1 with a melting point of 135-136. 2,2-Bisfluoromethyl-6-trifluoromethyl-2H-1 benzopyran-14-carbamide was obtained.
- 6-Pentafluoroethyl-1,2,2-bisfluoromethyl-1 2H-1-benzopyran-14-force Rubonic acid in the same manner as in Example 10 with melting point 144-145 ° C N — (2-cyanoethyl) -1-6-pentylfluoroethyl-2,2-bisfluoromethyl-12H-1-benzopyran-14-carbamide was obtained.
- N- (2-cyanoethyl) 1-Venzopyran-1 4-carbonamido 0.17 g of C was obtained.
- N- (2-Cyanoethyl) -1,2,2-bisfluoromethyl-1,3,4-dihydro-6-nitro-1H-2-benzo-pyran-14-carbothioamide was obtained.
- Example 21 Similar to Example 21 (1) using N- (2-cyanoethyl) -1,2,2-bisfluoromethyl-6-two-trough, 2H-1, one-benzopyran, and one-one lupamide.
- 0.34 g of 6-amino-N- (2-cyanoethyl) -1,2,2-bisfluoromethyl-1H-2-benzopyran-14-carbamide was obtained as an oil.
- Example 29 Using N- (2-cyanoethyl) -1,2,2-bisfluoromethyl-6-iodine-2H-1-benzopyran-14-carbamide, a similar method to Example 26 (1)
- Example 29 N- (2-cyanoethyl) -16-pentafluoromethyl-2,2-bisfluoromethyl-12H-1-1-benzopyran-14-carbamide represented by the following formula was obtained.
- 2-fluoromethyl-N with a melting point of 141-144 ° C was obtained in the same manner as in Example 8 by using 2-fluoromethyl-N, 2-dimethyl-6-nitro-2H-1-benzopyran-14-carbamide. There was obtained 2-dimethyl-6-two-row 2H-1-benzopyran-14-carbothioamide.
- N- (2-cyanoethyl) oily N- (2-cyanoethyl) was obtained in the same manner as in Example 16 using 12-fluoromethyl-2-methyl-6-nitro-12H-1-benzopyran-14-carbamide. 1) 2-Fluoromethyl-2-methyl-6-nitro-12H-1-benzopyran-14-carbothioamide was obtained.
- the obtained organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- a mixture of 50 ml of ethyl alcohol and 2 ml of sulfuric acid was added to the obtained residue, and the mixture was heated under reflux for 2 hours.
- the reaction mixture was concentrated to half the volume under reduced pressure, water was added to the residue, and the mixture was extracted with methylene chloride.
- the obtained organic layer was washed with saturated saline, dried over sodium sulfate and concentrated under reduced pressure.
- 6-Chloro-2,2-bisfluoromethyl-2H- 1-benzopyran-14-forced ruponic acid was used.
- 6-chloro N- (2 —Cyanoethyl) 1,2,2-Bisfluoromethyl-2H—1 Benzopyran-14-carbamide was obtained.
- the thoracic aorta was removed from a male Sprague Dawle rat (450-600 g) and used as a 2 mm-width annular specimen.
- the specimen Krebs-Henseleit solution (N a C 1: 119, KC 1: 4.8, CaC l 2 - 2H 2 0: 2.53, KH 2 P0 4: 1. 2, MgS0 4 ⁇ 7H 2 0: 1.2, NaHC0 3 : 24.8, glucose:. 10 (m M) 37 ° C) was suspended under tension force 2 g of the organ bath (Organ bath bath) of 10ml containing, vent the 95% 0 2, 5% C0 2 gas I let it.
- the contractile response of the specimen was recorded isometrically with an FD pickup. 1 After equilibration for 1.5 hours, add 3 OmM KC1 to shrink the tissue and relax the continuous contraction by KC1. The activity of the test compound to be alleviated was evaluated by determining the 50% inhibitory concentration (IC 50 ).
- cromakalim was used as the compound of the present invention obtained in the above example and a comparative control compound.
- Table 2 The results are shown in Table 2 below.
- Trachea were removed from male Hartley guinea pigs (450-550 g) and used as chain specimens.
- the specimen is suspended in a bath containing the above Krebs-Hen seleit solution (37 ° C) aerated with 95% O 2 and 5% CO 2 gas, and the contractile response of the specimen isometrically measured under 1 g tension. Recorded.
- test compound was used in the same manner as in Test Example 1.
- Table 2 shows the results.
- the effects of the compounds of the present invention are shown in the table below.
- the effect was expressed as the compound dose (ED 50 , mgZkg) required to suppress the histamine-induced increase in airway pressure by 50%.
- the novel compound of the present invention has an excellent K + channel activating effect, and is therefore expected to make a great contribution to the technical field such as a pharmaceutical composition (for example, an anti-asthmatic agent) utilizing the K + channel activating effect. Is done.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93902526A EP0632033B1 (en) | 1992-01-24 | 1993-01-25 | Novel benzopyran derivative |
DK93902526T DK0632033T3 (da) | 1992-01-24 | 1993-01-25 | Nye benzopyranderivater |
KR1019940702541A KR100217167B1 (ko) | 1992-01-24 | 1993-01-25 | 신규 벤조피란 유도체 |
DE69324354T DE69324354T2 (de) | 1992-01-24 | 1993-01-25 | Neue benzopyranderivate |
US08/256,580 US5646308A (en) | 1992-01-24 | 1993-01-25 | Benzopyran derivatives |
GR990401664T GR3030581T3 (en) | 1992-01-24 | 1999-06-22 | Novel benzopyran derivative. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/10819 | 1992-01-24 | ||
JP1081992 | 1992-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993015068A1 true WO1993015068A1 (en) | 1993-08-05 |
Family
ID=11760967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000086 WO1993015068A1 (en) | 1992-01-24 | 1993-01-25 | Novel benzopyran derivative |
Country Status (15)
Country | Link |
---|---|
US (1) | US5646308A (ja) |
EP (1) | EP0632033B1 (ja) |
JP (1) | JP3260458B2 (ja) |
KR (1) | KR100217167B1 (ja) |
CN (1) | CN1036918C (ja) |
AT (1) | ATE178601T1 (ja) |
AU (1) | AU3367393A (ja) |
CA (1) | CA2128603A1 (ja) |
DE (1) | DE69324354T2 (ja) |
DK (1) | DK0632033T3 (ja) |
ES (1) | ES2132217T3 (ja) |
GR (1) | GR3030581T3 (ja) |
SG (1) | SG52734A1 (ja) |
WO (1) | WO1993015068A1 (ja) |
ZA (1) | ZA93436B (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597818A (en) * | 1991-12-03 | 1997-01-28 | Merck & Co., Inc. | Methods of treating cardiac arrhythmia |
US5631251A (en) * | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
US5658901A (en) * | 1994-08-18 | 1997-08-19 | Merck & Co., Inc. | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines |
US5691332A (en) * | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
US5691331A (en) * | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
US5700797A (en) * | 1995-06-07 | 1997-12-23 | Merck & Co, Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
US5726171A (en) * | 1995-06-07 | 1998-03-10 | Merck & Co Inc | N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides |
WO1998038992A1 (fr) * | 1997-03-03 | 1998-09-11 | Chugai Seiyaku Kasushiki Kaisha | Medicaments destines aux troubles de la circulation peripherique |
EP1004316A4 (en) * | 1997-08-08 | 2003-02-12 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST COMPLICATIONS AT DIABETIS |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646310A (en) * | 1993-04-23 | 1997-07-08 | Chugai Seiyaku Kabushiki Kaisha | N-(2-cyanoethyl)-6-fluoroalkyl-2h-1-benzopyran derivatives |
WO1995013272A1 (fr) | 1993-11-10 | 1995-05-18 | Japan Tobacco Inc. | Derive de chromanne et utilisation therapeutique de ce dernier |
US6218427B1 (en) * | 1996-08-27 | 2001-04-17 | Shionogi & Co., Ltd. | Chromene-3-carboxylate derivatives |
FR2756284B1 (fr) * | 1996-11-26 | 2000-04-28 | Adir | Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP1120412A4 (en) * | 1998-09-30 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | PROCESSES FOR THE PREPARATION OF 4-SUBSTITUTED BENZOPYRAN DERIVATIVES |
CZ20013076A3 (cs) * | 2000-08-29 | 2002-04-17 | Kuraray Co., Ltd. | Způsob výroby chromankarboxylové kyseliny |
KR100602191B1 (ko) * | 2004-03-10 | 2006-07-19 | 한국화학연구원 | 5-라이폭시게네이즈 저해활성을 가지는2,2'-이중치환-3,4-디하이드로-7,8-이중치환-6-알킬아미노벤조피란 유도체 |
ES2338668T3 (es) * | 2004-05-05 | 2010-05-11 | F. Hoffmann-La Roche Ag | Arilsulfonil benzodioxanos utiles para la modulacion del receptor 5-ht6 y del receptor 5-ht2a o ambos. |
MX2007000911A (es) | 2004-07-30 | 2007-04-12 | Torrent Pharmaceuticals Ltd | Nevibolol y sus sales farmaceuticamente aceptables, proceso para su preparacion y composiciones farmaceuticas de nevibolol. |
WO2006066756A1 (en) | 2004-12-21 | 2006-06-29 | F. Hoffmann-La Roche Ag | Chroman derivatives and uses thereof in the treatment of cns disorders |
DK1831159T3 (da) * | 2004-12-21 | 2010-03-22 | Hoffmann La Roche | Tetralin og indanderivater samt anvendelser deraf |
RU2388748C2 (ru) * | 2004-12-21 | 2010-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные тетралина и индана и их применения в качестве антагонистов 5-нт |
KR100899061B1 (ko) * | 2004-12-21 | 2009-05-25 | 에프. 호프만-라 로슈 아게 | 테트랄린 및 인단 유도체 및 이의 용도 |
AU2005318596B2 (en) * | 2004-12-21 | 2010-12-23 | F. Hoffmann-La Roche Ag | Chroman derivatives and their use as 5-HT receptor ligands |
KR100704009B1 (ko) * | 2005-08-30 | 2007-04-04 | 한국화학연구원 | 염증억제 활성을 가지는6-알킬아미노-2-메틸-2'-(n-메틸치환술폰아미도)메틸-2h-1-벤조피란 유도체 |
CN101300246A (zh) * | 2005-11-03 | 2008-11-05 | 弗·哈夫曼-拉罗切有限公司 | 作为5-ht6抑制剂的芳基磺酰基色满类化合物作为蛋白激酶抑制剂的吲哚基马来酰亚胺衍生物 |
BRPI0713736A2 (pt) * | 2006-06-20 | 2014-11-18 | Hoffmann La Roche | Derivados de tetralina e indano e emprego destes |
KR101064001B1 (ko) * | 2006-06-20 | 2011-09-08 | 에프. 호프만-라 로슈 아게 | 아릴설폰아미딜 테트랄린 유도체 및 이의 용도 |
BRPI0713742A2 (pt) * | 2006-06-20 | 2013-02-13 | Hoffmann La Roche | derivados de arilsulfonila naftaleno e usos destes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57167981A (en) * | 1981-04-08 | 1982-10-16 | Kowa Co | Benzopyran derivative |
WO1992002514A1 (en) * | 1990-07-27 | 1992-02-20 | Chugai Seiyaku Kabushiki Kaisha | Novel benzopyran derivative |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH619701A5 (ja) * | 1975-08-07 | 1980-10-15 | Bayer Ag | |
GB8911280D0 (en) * | 1989-05-17 | 1989-07-05 | Beecham Group Plc | Novel compounds |
-
1993
- 1993-01-21 ZA ZA93436A patent/ZA93436B/xx unknown
- 1993-01-22 CN CN93102056A patent/CN1036918C/zh not_active Expired - Fee Related
- 1993-01-22 JP JP00942193A patent/JP3260458B2/ja not_active Expired - Fee Related
- 1993-01-25 US US08/256,580 patent/US5646308A/en not_active Expired - Fee Related
- 1993-01-25 EP EP93902526A patent/EP0632033B1/en not_active Expired - Lifetime
- 1993-01-25 WO PCT/JP1993/000086 patent/WO1993015068A1/ja active IP Right Grant
- 1993-01-25 AT AT93902526T patent/ATE178601T1/de not_active IP Right Cessation
- 1993-01-25 KR KR1019940702541A patent/KR100217167B1/ko not_active IP Right Cessation
- 1993-01-25 SG SG1996008501A patent/SG52734A1/en unknown
- 1993-01-25 ES ES93902526T patent/ES2132217T3/es not_active Expired - Lifetime
- 1993-01-25 AU AU33673/93A patent/AU3367393A/en not_active Abandoned
- 1993-01-25 DE DE69324354T patent/DE69324354T2/de not_active Expired - Fee Related
- 1993-01-25 CA CA002128603A patent/CA2128603A1/en not_active Abandoned
- 1993-01-25 DK DK93902526T patent/DK0632033T3/da active
-
1999
- 1999-06-22 GR GR990401664T patent/GR3030581T3/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57167981A (en) * | 1981-04-08 | 1982-10-16 | Kowa Co | Benzopyran derivative |
WO1992002514A1 (en) * | 1990-07-27 | 1992-02-20 | Chugai Seiyaku Kabushiki Kaisha | Novel benzopyran derivative |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597818A (en) * | 1991-12-03 | 1997-01-28 | Merck & Co., Inc. | Methods of treating cardiac arrhythmia |
US5658901A (en) * | 1994-08-18 | 1997-08-19 | Merck & Co., Inc. | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines |
US5631251A (en) * | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
US5691332A (en) * | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
US5691331A (en) * | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
US5700797A (en) * | 1995-06-07 | 1997-12-23 | Merck & Co, Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
US5726171A (en) * | 1995-06-07 | 1998-03-10 | Merck & Co Inc | N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides |
WO1998038992A1 (fr) * | 1997-03-03 | 1998-09-11 | Chugai Seiyaku Kasushiki Kaisha | Medicaments destines aux troubles de la circulation peripherique |
EP1004316A4 (en) * | 1997-08-08 | 2003-02-12 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST COMPLICATIONS AT DIABETIS |
Also Published As
Publication number | Publication date |
---|---|
ES2132217T3 (es) | 1999-08-16 |
KR100217167B1 (ko) | 1999-09-01 |
ZA93436B (en) | 1993-08-25 |
EP0632033B1 (en) | 1999-04-07 |
US5646308A (en) | 1997-07-08 |
GR3030581T3 (en) | 1999-10-29 |
DE69324354T2 (de) | 1999-11-25 |
KR950700277A (ko) | 1995-01-16 |
CA2128603A1 (en) | 1993-08-05 |
EP0632033A4 (ja) | 1995-02-01 |
CN1036918C (zh) | 1998-01-07 |
AU3367393A (en) | 1993-09-01 |
ATE178601T1 (de) | 1999-04-15 |
DK0632033T3 (da) | 1999-10-18 |
CN1077954A (zh) | 1993-11-03 |
JPH05294954A (ja) | 1993-11-09 |
EP0632033A1 (en) | 1995-01-04 |
DE69324354D1 (de) | 1999-05-12 |
JP3260458B2 (ja) | 2002-02-25 |
SG52734A1 (en) | 1998-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993015068A1 (en) | Novel benzopyran derivative | |
EP0706524B1 (en) | Processes and intermediates for the preparation of 5- 2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one | |
CA1273632A (en) | Cyclopenta(d)pyrimidine derivatives their preparation and use | |
CA3063111A1 (en) | Histone deacetylases (hdacs) inhibitors | |
JP2005526070A (ja) | オキソ−アザ二環系化合物 | |
JP3210665B2 (ja) | 新規なベンゾピラン誘導体 | |
EP0650964A1 (en) | 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives | |
JPH0366681A (ja) | クロマン誘導体 | |
WO2002066457A1 (fr) | Derive benzo[b]thiophene et procede de production correspondant | |
JPH04211084A (ja) | イミダゾピリダジン誘導体、その用途及び製造法 | |
EP0289371A1 (fr) | Dérivés d'imidazopyridines, leur préparation et leur application en thérapeutique | |
US20050245750A1 (en) | Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative | |
SK279095B6 (sk) | Deriváty chrómanu samy osebe a na liečenie chorôb, | |
Suzuki et al. | Synthesis and cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of heterocycle condensed purines | |
JP3535565B2 (ja) | ベンゾピラン誘導体 | |
EP0702952B1 (en) | Benzopyran derivatives | |
JP3352776B2 (ja) | ベンゾピラン及びベンゾオキサジン誘導体 | |
GB2039475A (en) | Tetrahydrox-anthones | |
JPS6043068B2 (ja) | アゼピノ〔1,2,3−1m〕−β−カルボリン誘導体及びその製法 | |
CN116143753A (zh) | Nlrp3抑制剂化合物 | |
JPS6263564A (ja) | インド−ル誘導体 | |
JPH0733769A (ja) | ピラゾロピリジン誘導体及びその製造法 | |
JPS61225174A (ja) | 新規1.4−チアジン誘導体 | |
JPH04342569A (ja) | キノリノン化合物 | |
JPH07196644A (ja) | ベンゾピラン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08256580 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2128603 Country of ref document: CA Ref document number: 1993902526 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1993902526 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993902526 Country of ref document: EP |